MissionIR Articles

When it comes to modern medicine, stem cells are seen as playing an increasingly important role, a role unmatched by anything else. Pluripotent stem cells, including induced pluripotent stem cells (adult cells that have been…

According to Dr. Ralph Snodgrass, President and Chief Scientific Officer and co-founder of VistaGen, a biotechnology company applying stem cell technology for drug rescue, cardiotoxicity (heart toxicity) has been implicated in almost 30% of drug…

On November 19, 2010, the U.S. Food & Drug Administration formally banned the sale on the American drug market of Darvon, a popular dextropropoxyphene made by Eli Lilly for pain relief. For many years Darvon…

VistaGen Therapeutics, a biotechnology company focused on using human stem cell technology for drug rescue and cell therapy, has been proactive in seeking strategic partnerships with other companies and research teams, all in an effort…

Of all the factors contributing to the success of VistaGen Therapeutics, a biotechnology company developing human pluripotent stem cell technology for drug rescue and cell therapy, perhaps the most important is the company’s long-term Sponsored…

VistaGen Therapeutics, Inc., a biotechnology company applying stem cell technology for drug rescue and cell therapy, and Synterys, Inc., a medicinal chemistry and collaborative drug discovery company, today jointly announced a strategic medicinal chemistry services…

MissionIR today announces that its interview with Shawn Singh, the Chief Executive Officer of VistaGen Therapeutics, is now available online. The complete interview can be heard at http://www.vsta.missionir.com/vsta-12-11.mp3. Mr. Singh provided a brief overview of…

VistaGen, a biotechnology company applying human pluripotent stem cell technology to drug rescue and cell therapy, is able to take advantage of a science advisory board with a wealth of experience in dealing with the…

On Thursday last week, when PPD, Inc., a leading global contract research organization, gave a presentation relating to current issues in cardiac safety, and the impact it has on drug development, it was clearly a…

VistaGen Therapeutics, Inc., a biotechnology company applying stem cell technology for drug rescue and cell therapy, and the University Health Network (UHN), one of Canada’s largest research hospitals, today announced the expansion of their existing…

VistaGen, a biotechnology company best known for applying human pluripotent stem cell technology to drug rescue, is also developing AV-101, a unique prodrug candidate for the treatment of neuropathic pain. AV-101 is orally available, converted…

Few would dispute the fact that more progress has been made in medicine and the overall science of healthcare in the past century than in all of the previous centuries put together. If there’s a…

It makes no difference how effective a new drug candidate is in the fight against cancer or other deadly disease. It also makes no difference how much effort, time, or money has gone into the…

VistaGen Therapeutics, Inc., a biotechnology company applying stem cell technology for drug rescue and cell therapy, just announced the publication of original research funded by the Company that identifies an antibody useful in the identification…

In a recent poster presentation given at the fourth Symposium on Cardiovascular Regenerative Medicine hosted by the National Institutes of Health’s National Heart, Lung and Blood Institute, VistaGen Therapeutics, a biotechnology company applying human pluripotent…

VistaGen Therapeutics is center stage in one of the most important developments in recent history for the pharmaceutical industry. The California biotechnology company is set to use stem cell technology to transform the way new…

Over the past decade, the number of new drugs approved by the FDA has dropped by a full 50%, despite major increases in research and development by the pharmaceutical industry. It’s not unusual for a…

VistaGen Therapeutics, Inc., a biotechnology company applying stem cell technology for drug rescue and cell therapy, announced today a poster presentation of its research and development activities leading to validation of its human stem cell-derived…

One of the biggest developments in mining today is the re-evaluation and activation of existing gold mines. The reason is obvious. The price of gold has exploded over the past decade, making previously marginal gold…

VistaGen Therapeutics, Inc., a biotechnology company applying stem cell technology for drug rescue and cell therapy, was pleased to announce today the issuance of two additional United States patents supporting its therapeutic and drug discovery…